title: A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320.
authors.affiliation: a Cancer Research UK and University College London Cancer Trials Centre , London , UK ;
authors.forename: William
authors.initials: W
authors.lastname: Townsend
authors.affiliation: b The Leeds Teaching Hospitals NHS Trust , Leeds , UK ;
authors.forename: Rod J
authors.initials: RJ
authors.lastname: Johnson
authors.affiliation: c Royal Cornwall Hospitals NHS Trust , Truro , UK ;
authors.forename: Bryson T
authors.initials: BT
authors.lastname: Pottinger
authors.affiliation: a Cancer Research UK and University College London Cancer Trials Centre , London , UK ;
authors.forename: Nicholas
authors.initials: N
authors.lastname: Counsell
authors.affiliation: a Cancer Research UK and University College London Cancer Trials Centre , London , UK ;
authors.forename: Paul
authors.initials: P
authors.lastname: Smith
authors.affiliation: a Cancer Research UK and University College London Cancer Trials Centre , London , UK ;
authors.forename: Humra
authors.initials: H
authors.lastname: Chadwick
authors.affiliation: d Department of Haematology , Royal Devon and Exeter NHS Foundation Trust , Exeter , Devon EX2 5AD , UK.
authors.forename: Katy
authors.initials: K
authors.lastname: Evans
authors.affiliation: d Department of Haematology , Royal Devon and Exeter NHS Foundation Trust , Exeter , Devon EX2 5AD , UK.
authors.forename: Caroline
authors.initials: C
authors.lastname: Wickham
authors.affiliation: d Department of Haematology , Royal Devon and Exeter NHS Foundation Trust , Exeter , Devon EX2 5AD , UK.
authors.forename: Claudius E
authors.initials: CE
authors.lastname: Rudin
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000009:adverse effects; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D013792:Thalidomide / Q000008:administration & dosage* / Q000009:adverse effects; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D013792:Thalidomide; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine